

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/11, 15/85, C07H 21/04 C07K 15/00, 15/12, A61K 37/02 A61K 31/73, 43/00	A1	(11) International Publication Number: WO 94/09128 (43) International Publication Date: 28 April 1994 (28.04.94)
(21) International Application Number: PCT/US93/10074 (22) International Filing Date: 20 October 1993 (20.10.93) (30) Priority data: 07/965,678 22 October 1992 (22.10.92) US (71) Applicant: MALLINCKRODT MEDICAL, INC. [US/ US]; 675 McDonnell Boulevard, P.O. Box 5840, St. Lo- uis, MO 63134 (US). (72) Inventor: LYLE, Leon, R. ; 1319 Webster Path Drive, Web- ster Groves, MO 63119 (US). (74) Agents: VACCA, Rita, D. et al.; Mallinckrodt Medical, Inc., 675 McDonnell Boulevard, P.O. Box 5840, St. Lo- uis, MO 63134 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: THERAPEUTIC TREATMENT FOR INHIBITING VASCULAR RESTENOSIS (57) Abstract A composition suitable for administration to a warm-blooded animal comprising antisense MCP-1 peptide or oligonucleo- tide or a molecule capable of interacting with MCP-1 peptide or information for its synthesis which may or may not be labeled with a radionuclide by means of a chelate ligand capable of administration to an animal to produce reliable visual imaging of areas of potential restenosis or to produce therapeutic effects on areas of potential restenosis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

THERAPEUTIC TREATMENT FOR INHIBITING
VASCULAR RESTENOSIS

FIELD OF THE INVENTION

This invention relates generally to novel
5 compounds for therapeutic use, and more particularly, to
specific molecularly interactive compounds, to methods of
preparing and using such specific compounds, and to
pharmaceutical compositions comprising these specific
compounds for therapeutic use in areas of vascular injury,
10 sites of inflammation, vascular atheromatous disease and/or
restenosis.

BACKGROUND OF THE INVENTION

Balloon angioplasty, atherectomy, rotatory
ablation and similar therapeutic techniques used to improve
15 circulation in vivo are finding ever-increasing application
in therapeutic cardiology. Generally, balloon angioplasty
procedures involve the introduction of a balloon-type
catheter into the narrowed portion of an artery. The
narrowing of the artery may be caused by different factors
20 but most commonly is caused by a build-up of
"atherosclerotic plaque". Once the catheter is positioned
in the narrowed portion of the artery, the balloon portion
of the catheter is inflated. The inflation of the balloon
within the narrowed area of the artery serves to increase
25 the diameter of the blood vessel thus improving
circulation.

Often times, following a balloon angioplasty
therapeutic procedure or similar therapeutic technique with
attendant vascular injury, patients experience a re-
30 narrowing or restenosis, of the artery within six months
after having undergone the angioplasty therapeutic

treatment or after incurring the particular vascular injury. Restenosis is of considerable concern since its effects may be life threatening.

Therefore, the need for a suitable compound for
5 therapeutic use to prevent restenosis following balloon angioplasty or similar therapeutic techniques which may cause vascular injury is of significant importance. It is an object of the present invention to meet this need.

SUMMARY OF THE INVENTION

10 The present invention discloses novel peptide, polypeptide and oligonucleotide compounds, methods of preparing these compounds, pharmaceutical compositions comprising these compounds and the use of these compounds in balloon-type catheters for therapeutic treatment to
15 inhibit vascular restenosis. Restenosis is a recurrent stenosis, i.e., a narrowing or stricture of a duct or canal. Restenosis and the development of atheromatous lesions (the reason for the procedure in the first place) share several common pathological elements such as the
20 accumulation of monocytes and macrophages at the area of injury or inflammation and the proliferation of vascular smooth muscle. Growth factors which induce this proliferation of vascular smooth muscle and thus cause restenosis, arise from the monocytes and macrophages which
25 infiltrate the injured area in response to inflammatory stimuli. The monocytes and macrophages present in the tissue represent stages of differentiation of the same cell lineage. The cells are referred to as monocytes when in the blood. Upon deposition in tissue, the cells are called
30 macrophages.

Monocyte Chemotactic Protein-1, hereinafter

referred to as "MCP-1" is a member of the "C-C" family of chemokines. It is a potent stimulator of monocyte chemotaxis and has an extremely high degree of specificity for this cell type. Other family members include Human
5 Macrophage Inflammatory Protein-1 (HuMIP-1) alpha and beta, Monocyte Chemotactic Protein-2 (MCP-2), RANTES and I-309. All of these cytokines incorporate a cysteine cysteine (CC) motif, but MCP-1 is the one most highly specific for monocytes and macrophages. MCP-1 is produced by injured
10 vascular smooth muscle cells. The MCP-1 so produced attracts the monocytes and macrophages which infiltrate the area releasing growth factors and resulting in proliferation of vascular smooth muscle and restenosis.

In using a molecularly interactive therapeutic
15 compound to inhibit vascular restenosis as discussed herein, the compound must be highly selective. High selectivity, which is essential in such therapeutic compounds, means that the compound, after having been introduced into the body, accumulates to a greater degree
20 in the target tissue or tissues, i.e. the area of possible restenosis, than in surrounding tissues. In using peptides, polypeptides or oligonucleotides as therapeutic compounds, the specific high selectivity of the particular agent used provides for the strong accumulation of the
25 therapeutic compound in the specific tissue or tissues targeted. In the case of the present invention, the site of accumulation is in areas of injured vascular smooth muscle cells as compared with the accumulation and concentration thereof in other non-target tissues.

30

DETAILED DESCRIPTION OF THE INVENTION

In the present invention, a balloon-type catheter such as a balloon infusion catheter is coated or filled

with a total, partial or synthetic antisense peptide or oligonucleotide to a monocyte chemoattractant protein (MCP) material, such as monocyte chemoattractant protein-1 (MCP-1), a member of the CC family of chemotactic cytokines or chemokines hereinafter referred to as "antisense MCP-1". An antisense peptide is specified by the DNA strand complementary to that which specifies the ordinary sense peptide. These sense peptides function by "hydropathic complimentoiety" to give binding activity with its corresponding sense peptides and can function as receptor like molecules in affinity chromatography as explained by Souza, S.J.U. and Bretani, R. J., Biol. Chem. 267: 13763-13773 (1992). When an antisense peptide is used, one obtains complimentary binding to and inactivation of the mature MCP-1 polypeptide. When an antisense oligonucleotide is used, this antisense oligonucleotide to MCP-1 inhibits the translation or transcription of MCP-1 mRNA within the vascular smooth muscle cells or surrounding interstitial space. Accordingly, MCP-1 production is severely inhibited. In the absence of MCP-1, monocytes are not attracted to the area of vascular injury in their usual numbers. As a result of the monocytes not infiltrating the area, growth factors (GFs) are not released. The relative lack of GFs does not support the proliferation of vascular smooth muscle cells which cause restenosis in cases of vascular injury.

Therapeutic treatment of vascular restenosis can also be achieved and augmented through the use of another embodiment of the present invention whereby the antisense MCP-1 polypeptide or oligonucleotide is labelled with a radionuclide for therapeutic use. Radiolabelled antisense MCP-1 compounds for therapeutic use may be constructed using high energy alpha or beta emitting isotopes rather than the pure gamma emitters customarily used for

5

diagnostic purposes which is also possible and will be discussed in more detail below.

The sense MCP-1 polypeptide sequence is as follows:

5 NH₂-X P D A I N A P V T C C Y N F T N R K I S V
 Q R L A S Y R R I T S S K C P K E A V I F K T I
 V A K E I C A D P K Q K W V Q D S M D H L D K Q
 T Q T P K T-COOH

wherein A represents Alanine, B represents Asparagine or
10 Aspartic Acid, C represents Cysteine, D represents
 Aspartic Acid, E represents Glutamic Acid, F represents
 Phenylalanine, G represents Glycine, H represents
 Histidine, I represents Isoleucine, K represents Lysine,
 L represents Leucine, M represents Methionine, N
15 represents Asparagine, P represents Proline, Q represents
 Glutamine, R represents Arginine, S represents Serine, T
 represents Threonine, V represents Valine, W represents
 Tryptophan, X represents an unspecified or variable amino
20 Acid.

The antisense MCP-1 of the present invention is represented by the following sequence:

25 NH₂ X G L R X L R G X X T T X L K X L X F X X X
 V X X R X X X X X X X X F T G F L R X X K F X X
 X R F L X T R L G F V F T X V L X Y L V X L F V
 X V X G F X COOH

The antisense oligonucleotide ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequences are:

RNA:

5'-NNN CCN GAY GCN AUH AAY GCN CCN GUN ACN UGY
 5 UGY UAY AAY UUY ACN AAY MGN AAR AUH WSN GUN CAR
 MGN YUN GCN WSN UAY MGN MGN AUH ACN WSN WSN AAR
 UGY CCN AAR GAR GCN GUN AUH UUY AAR ACN AUH GUN
 GCN AAR GAR AUH UGY GCN GAY CCN AAR CAR AAR UGG
 GUN CAR GAY WSN AUG GAY CAY YUN GAY AAR CAR ACN
 10 CAR ACN CCN AAR ACN -3'; and

DNA:

5'-NNN CCN GAY GCN ATH AAY GCN CCN GTN ACN TGY
 TGY TAY AAY TTY ACN AAY MGN AAR ATH WSN GTN CAR
 MGN YTN GCN WSN TAY MGN MGN ATH ACN WSN WSN AAR
 15 TGY CCN AAR GAR GCN GTN ATH TTY AAR ACN ATH GTN
 GCN AAR GAR ATH TGY GCN GAY CCN AAR CAR AAR TGG
 GTN CAR GAY WSN ATG GAY CAY YTN GAY AAR CAR ACN
 CAR ACN CCN AAR ACN -3',

wherein A=Adenine, T=Thymine, C=Cytosine, G=Guanine,
 20 U=Uracil, B=not A, D=not C, F=not G, K=G or T, M=A or C,
 N=A, C, G or T, R = A or G, S=C or G, V=not T, W=A or T and
 Y=C or T.

In targeting mature MCP-1 polypeptide with
 antisense MCP-1 polypeptide, it is not necessary that the
 25 complete seventy-six (76) residue sequence be present.
 Effective complementary binding may reside in a smaller
 portion of the molecule. Through substitution in the
 antisense MCP-1 polypeptide sequence, and perhaps
 incorporating (d) amino acid enantiomorphs, retroinverse

bonds and the like, additional useful peptides are developed without affecting complementary binding specificity and affinity desired.

Similarly in targeting oligonucleotides into smooth muscle cells it is not necessary that the entire oligonucleotide sequence be present. It is also useful to replace some oxygen atoms in the phosphate backbone with thiol groups to inhibit degradation in vivo.

In the present invention, the antisense MCP-1 polypeptide or oligonucleotide or a molecule having similar specificity, may be administered in vivo using a balloon infusion catheter with holes in it for delivery to the particular target site to prevent life-threatening restenosis. The antisense MCP-1 polypeptide or oligonucleotide may also be radiolabelled prior to administration, using more than one method. The objective in radiolabeling is to increase therapeutic effect, by bringing this cytotoxic properly to bear upon smooth muscle. The reaction in radiolabelling peptides generally takes place between the amino groups in the peptide and the carbonyl group in the active ester of a specific ligand to form an amide bond. In particular, the peptides can be radiolabelled using either a conventional method referred to as "post-formed chelate approach" or by a recent method referred to as "pre-formed chelate approach" developed by Fritzberg et al., U.S. Patent Numbers 4,965,392 and 5,037,630 incorporated herein by reference. In the "pre-formed approach," the desired ligand is complexed with the radionuclide and then conjugated to antisense MCP-1 polypeptide or a molecule having antisense MCP-1 activity. In the "post-formed approach," the desired ligand is first conjugated to the antisense peptide and the resulting

conjugate is incubated with the radionuclide along with a reducing agent. In the present invention, the latter approach has the additional advantage of allowing preparation of the complex in kit form. Users merely add

- 5 the radionuclide to the ligand antisense MCP-1 conjugate or a derivative thereof for labelling to occur.

It is important to note an unique mechanism of the present invention whereby the conjugation reaction will only occur when the amino group is in the "free base" form, i.e., deprotonated to the NH_2 form. If the amino group is protonated, i.e., in the NH_3^+ form, the reaction will not occur. Therefore, in the molecules of the present invention it is potentially important to perform the conjugation at neutral pH or within the range of 7.0 to 9.5 to avoid deprotonation of epsilon-amino groups of lysine, or K. Avoiding the deprotonation of epsilon-amino groups involved in binding prevents the formation of a chelate complex which may interfere with the ability of the peptide to form a complementary complex with MCP-1. In the present invention, binding preferably occurs on the alpha amino group in order to avoid potential interference with the ability of the antisense MCP-1 peptide to form a complementary complex with sense.

Using either method of labelling antisense MCP-1, any suitable ligand can be used to incorporate the preferred radionuclide metal ion such as for example but not limited to technetium, rhenium, indium, gallium, samarium, holmium, yttrium, copper, or cobalt, and more particularly, yttrium-90, rhenium-188, rhenium-186, indium-111, technetium-^{99m}, and derivatives thereof. The choice of the ligand entirely depends on the type of metal ion desired for therapeutic or even diagnostic purposes. For example, if the radionuclide

is a transition element such as technetium or rhenium, then ligands containing amine, amide, and thiols are preferred to form a stable complex whereas if the radionuclide is a lanthanide element, then polyaminocarboxyates or phenolate type ligands are preferable.

The above-described unique characteristics of the present invention make the radiolabelled antisense MCP-1 polypeptide and its derivatives very attractive for therapeutic purposes or even diagnostic uses to identify sites of restenosis and/or vascular injury. The compounds of the present invention may be labelled with any radionuclide favorable for these purposes. Such suitable radionuclides for radiotherapy include but are not limited to rhenium-186, copper-67, rhenium-188 and cobalt-60. For diagnostic purposes the most suitable radionuclides include but are not limited to the transition metals as exemplified by technetium-99m and copper-62.

Due to the unique mechanism employed in the present invention to label the alpha amino group of antisense MCP-1 and avoid the epsilon amino group(s) (which could inhibit the ability of antisense MCP-1 peptides to bind to its complementary sense strand) a significantly advantageous radiolabelled peptide compound for radiotherapy and diagnostic imaging of areas of potential restenosis is achieved.

As previously noted, the preferred embodiment of the present invention is the peptide, polypeptide or protein antisense MCP-1 or derivatives thereof used alone to prevent vascular restenosis. However, additional embodiments of the present invention include antisense MCP-1 or derivatives thereof radiolabelled using a pre-formed or post-formed methodology.

In a preferred embodiment according to the present invention, antisense MCP-1 or a molecule having sense MCP-1 interactive capability is first bonded to the N₃S aminothiol ligand which is illustrated in Figure 1




Figure 1

wherein m is a whole number less than eleven and preferably 3; p is either 0 or 1; PG₁ is a suitable sulfur protecting group selected from the group consisting of C₁₋₂₀ S-acyl such as alkanoyl, benzoyl and substituted benzoyl -whereby alkanoyl is preferable, C₁₋₂₀ S-acyl groups such as benzyl, t-butyl, trityl, 4-methoxybenzyl and 2,4-dimethoxybenzyl -whereby 2,4-dimethoxybenzyl is preferable, C₁₋₁₀ alkoxyalkyl such as methoxymethyl, ethoxyethyl and tetrahydropyranyl -whereby tetrahydropyranyl is preferable, carbamoyl, and C₁₋₁₀ alkoxy carbonyl such as t-butoxycarbonyl and methoxycarbonyl -whereby t-butoxycarbonyl is preferable; and X is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imidate, maleimide, chlorocarbonyl, chlorosulfonyl, succinimidyl oxycarbonyl, haloacetyl and C₁₋₁₀ N-alkoxycarbamoyl -whereby N-methoxycarbamoyl is preferable.

In another preferred embodiment according to the present invention, antisense MCP-1 or a molecule having sense MCP-1 interactive capability is bonded to the N₂S₂ aminothiol ligand which is illustrated in Figure 2;




Figure 2

wherein n is a whole number less than eleven and preferably 3; PG₂ and PG₃ may be the same or different sulfur protecting groups selected from the group consisting of C₁₋₂₀ S-acyl such as alkanoyl, benzoyl and substituted benzoyl - whereby alkanoyl is preferable, C₁₋₂₀ alkyl groups such as benzyl, t-butyl, 4-methoxybenzyl, trityl and 2,4-dimethoxybenzyl -whereby 2,4-dimethoxybenzyl is preferable, C₁₋₁₀ alkoxyalkyl such as for example methoxymethyl, ethoxyethyl, and tetrahydropyranyl -whereby tetrahydropyranyl is preferable, carbamoyl and C₁₋₁₀ alkoxy carbonyl such as methoxycarbonyl, ethoxycarbonyl and t-butoxycarbonyl -whereby t-butoxycarbonyl is preferable; and Y is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imidate, maleimide, chlorocarbonyl, chlorosulfonyl, succinimidyl oxycarbonyl, haloacetyl, and C₁₋₁₀ N-alkoxycarbamoyl -whereby N-methoxycarbamoyl is preferable.

In another preferred embodiment of the present invention, antisense MCP-1 or a molecule having sense MCP-1 interactive capability is conjugated with the ligand illustrated in Figure 3,




Figure 3

wherein n varies from 1 to 10, and Y is a coupling moiety

selected from the group consisting of carboxyl, amino, isocyanate, isothioganate, imidate, maleimide, chlorocarbonyl, chlorosulfonyl, succinimidylloxycarbonyl, haloacetyl, and C₁₋₁₀ N-alkoxycarbamoyl such as N-methoxycarbamoyl and t-butoxycarbamoyl -whereby t-butoxycarbamoyl is preferable; and R is selected from the group consisting of hydrogen and C₁₋₁₀ alkyl such as methyl and t-butyl -whereby t-butyl is preferable.

In another preferred embodiment, the antisense MCP-1 or a molecule having sense MCP-1 interactive capability can be conjugated with the metal complex illustrated in Figure 4




Figure 4

wherein m is a whole number less than eleven and more preferably 3; p is either 0 or 1; X' is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imidate, maleimide, chlorocarbonyl, chlorosulfonyl, succinimidylloxycarbonyl, haloacetyl and C₁₋₁₀ N-alkoxycarbamoyl such as N-methoxycarbamoyl and t-butoxycarbamoyl -whereby t-butoxycarbamoyl is preferable and M is a radionuclide suitable for diagnostic imaging or therapeutic use such as technetium, rhenium, copper, cobalt, indium, gallium, samarium, yttrium and holmium.

In another preferred embodiment, the antisense MCP-1 or a molecule having sense MCP-1 interactive capability can be conjugated with a metal complex as

13

illustrated in Figure 5 wherein Y' and n are defined the same respectively as Y and n in Figure 3 and M is defined the same as M in Figure 4.




Figure 5

5 In another preferred embodiment, the antisense MCP-1 or a molecule having sense MCP-1 interactive capability can be conjugated with a metal complex as shown in Figure 6.




Figure 6

10 wherein Z', q and R are defined the same respectively as Y, n and R of Figure 3 and M is defined the same as M in Figure 4.

15 In another preferred embodiment, the antisense MCP-1 or a molecule having sense MCP-1 interactive capability can be conjugated with a metal complex as shown in Figure 7.




Figure 7

wherein M is defined the same as M in Figure 4.

Common esters which have been found useful in this labelling technique are o- and p- nitrophenyl, 2-chloro-4-nitrophenyl, cyanomethyl, 2-mercaptopyridyl, hydroxybenztriazole, N-hydroxysuccinimide, trichlorophenyl, tetrafluorophenyl, thiophenyl, tetrafluorothiophenyl, o-nitro-p-sulfophenyl, N-hydroxyphthalimide and the like. For the most part, the esters will be formed from the reaction of the carboxylate with an activated phenol, particularly, nitro-activated phenols, or a cyclic compound based on hydroxylamine.

The advantages of using sulfur protecting groups include the fact that a separate step for removal of the sulfur-protective group is not necessary. The protecting groups are displaced from the compound during the labelling in what is believed to be a metal-assisted acid cleavage: i.e., the protective groups are displaced in the presence of a radionuclide at an acid pH and the radionuclide is bound by the chelating compound. The radiolabeling procedure thus is simplified, which is a significant advantage when the chelating compounds are to be radiolabelled in a hospital laboratory shortly before use. Additionally, another advantage of the present invention is that the basic pH conditions and harsh conditions associated with certain known radiolabeling procedures or procedures for removal of other sulfur protected groups are avoided. Thus, base-sensitive groups on the chelating compounds survive the radio-labelling step intact.

Suitable sulfur-protecting groups, when taken together with the sulfur atom to be protected, include hemithioacetal groups such as ethoxyethyl, tetrahydrofuranyl, methoxymethyl, and tetrahydropyranyl. Other suitable sulfur protecting groups are C₁₋₂₀ acyl groups, preferably alkanoyl or benzoyl. Other possible formulas for the chelating compounds are described in U.S. Patent Number 4,965,392 incorporated herein by reference.

Synthesis of the radionuclide bifunctional chelate and subsequent conjugation to antisense MCP-1, or a derivative thereof, can be performed as described in U.S. Patent Number 4,965,392 incorporated herein by reference and related technologies as covered by U.S. patent numbers 4,837,003, 4,732,974 and 4,659,839, each incorporated herein by reference.

After purification, the radiolabelled antisense MCP-1, or derivatives thereof, may be injected into a patient for therapeutic use or even diagnostic imaging depending on the radionuclide used. The radiolabelled antisense MCP-1 compound of the present invention is capable of radiotherapeutic use or reliably visualizing areas of potential restenosis within minutes post-injection. The antisense MCP-1 peptide when radiolabelled with the Re-186 or Re-188 triamide thiolate bifunctional chelate is particularly efficacious as an in vivo radiotherapeutic agent for areas of restenosis.

Still another embodiment of the present invention is the introduction of an antisense oligonucleotide or the gene for the synthesis of antisense MCP-1 oligonucleotide into individual vascular smooth muscle cells in area(s) of vascular injury.

When introducing this antisense MCP-1 gene into the vascular smooth muscle cells, replication of the antisense MCP-1 is aided by placing it under the control of a tissue specific promoter such as the smooth muscle alpha

5 actin promoter to prevent life-threatening vascular restenosis.

Such introduction is affected by infusion with a high concentration of oligonucleotide into the smooth muscle tissues with a balloon infusion catheter. This
10 typically requires high pressure(s) (greater than 4 atmospheres) and high concentrations of oligonucleotides (greater than 12.5 micrograms per milliliter) and is aided by agents which help to increase the solubility of membranes such as lipid rich liposomes.

15 If based on RNA or DNA so as to bind to MCP-1 mRNA and prevent translation, the sequence to be introduced is derived from the RNA and DNA sequences previously given on pages 5 and 6.

It is important to note that effective inhibition
20 of translation need not require the entire sequence. Appropriate specificity and ability to inhibit may be conferred with a sequence of approximately 15 to 30 nucleotides.

As noted above, the cysteine cysteine (CC) motif
25 is a common feature characteristic of this family of chemokines and maintenance of this motif is a critical factor in preservation of biological activity. Therefore nucleotide sequences which would inhibit cysteine cysteine (CC) translation with preservation of specificity are
30 particularly effective. For example the antisense RNA

construct 5'- GUN ACN UGY UGY UAY AAY -3', or the DNA construct 5'- GIN ACN TGY TGY TAY AAY -3'.

In a further embodiment of this invention, therapeutic effects of antisense oligonucleotides upon
5 potentially proliferating smooth muscle cells are achieved by radiolabelling the antisense MCP-1 oligonucleotide with a suitable isotope such phosphorous 32 or phosphorous 33.

Each of the embodiments of the present invention are described in still greater detail in the illustrative
10 examples which follow:

Example 1:

A solution of antisense MCP-1 peptide, or derivatives thereof, (0.01 mmol) in 2 mL of carbonate/bicarbonate buffer at pH 8.5 ± 0.5 is treated
15 with a solution of 0.1 mmol of the ligand illustrated in Figure 1 (wherein $m=2$, $p=1$, PG_1 is benzoyl, and X is succinimidylloxycarbonyl) in dimethylformamide (0.5 mL) and the entire mixture is kept at room temperature for 2 hours. The mixture is then diluted with water (2.5 mL) and
20 dialyzed extensively against water. After dialysis, the solution is lyophilized to give the desired antisense MCP-1 conjugate.

Example 2:

A solution of antisense MCP-1 peptide, or
25 derivatives thereof, (0.01 mmol) in 2 mL of carbonate/bicarbonate buffer at pH 8.5 ± 0.5 is treated with a solution of 0.1 mmol of the ligand illustrated in Figure 2 (wherein $n=2$, PG_2 and PG_3 are benzoyl, and Y is succinimidylloxycarbonyl) in dimethylformamide (0.5 mL) and

the entire mixture is kept at room temperature for 2 hours. The mixture is then diluted with water (2.5 mL) and dialyzed extensively against water. After dialysis, the solution is lyophilized to give the desired antisense MCP-1
5 conjugate.

Example 3:

A solution of antisense MCP-1 peptide, or derivatives thereof, (0.01 mmol) in 2 mL of carbonate/bicarbonate buffer at pH 8.5 \pm 0.5 is treated
10 with a solution of 0.1 mmol of the ligand illustrated in Figure 3 (wherein q=4, and Z is succinimidylloxycarbonyl) in dimethylformamide (0.5 mL) and the entire mixture is kept at room temperature for 2 hours. The mixture is then diluted with water (2.5 mL) and dialyzed extensively
15 against water. After dialysis, the solution is lyophilized to give the desired antisense MCP-1 conjugate.

Example 4:

To 100 μ L of a solution containing 5 mg of sodium gluconate and 0.1 mg of stannous chloride in water, 500 μ L
20 of $^{99m}\text{TcO}_4$ (pertechnetate) is added. After incubation at room temperature for about 10 minutes, a solution of 500 μ L of the antisense MCP-1 polypeptide, or derivatives thereof, conjugates (1 mg/mL in 0.1 M carbonate/bicarbonate buffer, pH 9.5) as described in Examples 1 or 2 is then added and
25 the entire mixture is incubated at 37°C for about 1 hour. The desired labelled peptide is separated from unreacted ^{99m}Tc -gluconate and other small molecular weight impurities by gel filtration chromatography (Sephadex G-50) using phosphine buffered physiological saline, (hereinafter PBS),
30 0.15M NaCl, pH 7.4 as eluent.

Example 5:

A mixture of gentisic acid (25 mg), inositol (10

mg), and the antisense MCP-1 polypeptide, or derivatives thereof, conjugate (500 uL, 1 mg/mL in water) was treated with In-111 indium chloride in 0.05 M HCl. The solution was allowed to incubate at room temperature for about 30
5 minutes. The desired labelled peptide is separated from unreacted In-111 indium salts and other small molecular weight impurities by gel filtration chromatography (Sephadex G-50) using phosphine buffered physiological saline, (PBS), 0.15M NaCl as eluent.

10 Example 6:

Antisense RNA or DNA or a derivative thereof for purposes of inhibition of translation is prepared by oligonucleotide synthesis, suspended to a concentration of between 10 and 500 micrograms per milliliter in 10mM. Tris
15 chloride with 1mM ethylenediaminetetraacetic acid (EDTA) and infused into the lesion using a balloon infusion catheter at pressures of four to eight atmospheres. Contact time should be in the range of 5 to 30 minutes. If it is desired to radiolabel the preparation with phosphorus
20 -32 or phosphorus-33 to increase therapeutic effect, phosphorus-32 or phosphorus-33 labeled nucleotides are added by nick translation in the case of DNA or by templated synthesis in the case of RNA.

Example 7:

25 Antisense DNA or a derivative thereof for purposes of inhibition of MCP-1 synthesis by inhibition of transcription by self replication within smooth muscle cells is prepared by introduction of such DNA sequences into a plasmid (a circular piece of DNA) consisting of a
30 smooth muscle actin promoter coupled to antisense DNA to MCP-1 and appropriate start and stop signals. This plasmid is introduced into smooth muscle cells by using a balloon infusion catheter. The plasmid DNA is suspended to a

concentration of between 10 and 100 micrograms per milliliter in Tris chloride EDTA (10 mM, 1 mM EDTA) (TE) and is infused at a pressure of between 4 and 8 atmospheres. Infusion time varies between 5 and 30 minutes.

After the antisense MCP-1 polypeptide, oligonucleotide or a derivative thereof is prepared and optionally labelled according to the procedure described above, the compound is used with a pharmaceutically acceptable carrier in a method of performing therapy or radiotherapy or a method of performing a diagnostic imaging procedure using a gamma camera or like device. These procedures involve injecting or administering, for example by means of a balloon injector catheter, to a warm-blooded animal an effective amount of the present invention and then in the case of diagnostic use, exposing the warm-blooded animal to an imaging procedure using a suitable detector, e.g. a gamma camera. Images are obtained by recording emitted radiation of tissue or the pathological process in which the radioactive peptide or oligonucleotide has been incorporated, which in the present case are potential sites of restenosis, thereby imaging at least a portion of the body of the warm-blooded animal. Pharmaceutically acceptable carriers for either diagnostic or therapeutic use include those that are suitable for injection or administration such as aqueous buffer solutions, e.g. tris (hydroxymethyl)aminomethane (and its salts), chloride phosphate, citrate, bicarbonate, etc., sterile water for injection, physiological saline, and balanced ionic solutions containing chloride and/or bicarbonate salts of normal blood plasma cations such as Ca^{2+} , Na^{+} , K^{+} and Mg^{2+} . Other buffer solutions are described in Remington's Practice of Pharmacy, 11th edition, for

example on page 170. The carriers may contain a chelating agent, e.g. a small amount of ethylenediaminetetraacetic acid (EDTA), calcium, disodium salt, or other pharmaceutically acceptable chelating agents.

5 The concentration of the labelled or unlabelled peptide and the pharmaceutically acceptable carrier, for example in an aqueous medium, varies with the particular field of use. A sufficient amount is present in the pharmaceutically acceptable carrier in the present
10 invention when satisfactory visualization of areas of vascular injury is achievable or satisfactory therapeutic results are achievable.

 The composition is administered to the warm-blooded animals so that the composition remains in the
15 living animal for about six to seven hours, although shorter and longer residence periods are normally acceptable.

 The antisense MCP-1 compounds of the present invention or antisense MCP-1 derivative thereof, prepared
20 as described herein, provide means of in vivo therapeutic, radiotherapeutic or diagnostic imaging of areas of potential restenosis.

 After consideration of the above specification, it will be appreciated that many improvements and
25 modifications in the details may be made without departing from the spirit and scope of the invention. It is to be understood, therefore, that the invention is in no way limited, except as defined by the appended claims.

We claim:

1. A composition suitable for administration to a warm-blooded animal comprising an antisense MCP-1 peptide or a derivative thereof to inhibit vascular restenosis.
- 5 2. A method of in vivo vascular therapy, which comprises administering to a warm-blooded animal a therapeutically-effective amount of an antisense MCP-1 peptide or a derivative thereof to inhibit vascular restenosis.
3. An antisense MCP-1 peptide capable of inhibiting
10 vascular restenosis upon in vivo administration.
4. The antisense MCP-1 peptide of claims 1, 2, or 3 wherein said antisense MCP-1 peptide labeled with a radionuclide by means of a chelate is capable of administration to a warm-blooded animal to inhibit vascular
15 restenosis.
5. A therapeutic composition suitable for administration to a warm-blooded animal comprising an antisense MCP-1 peptide labeled with Re-186 or Re-188 by means of a triamide thiolate (N₃S) chelate capable of administration to
20 an animal to produce therapeutic effects on areas of restenosis.
6. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal a therapeutically-effective amount of an antisense MCP-1
25 peptide labeled with Re-186 or Re-188 by means of a triamide thiolate (N₃S) chelate to allow for therapeutic effects on areas of restenosis.
7. An antisense MCP-1 peptide labeled with Re-186 or Re-188 by means of a triamide thiolate (N₃S) chelate.

8. The antisense MCP-1 peptide of claims 5, 6, or 7 wherein said antisense MCP-1 peptide labeled with Re-186 or Re-188 Re by means of a triamide thiolate (N_3S) chelate is capable of administration to a warm-blooded animal to produce therapeutic effects on areas of restenosis post-administration.
9. A diagnostic composition suitable for administration to a warm-blooded animal comprising an antisense MCP-1 peptide labeled with a suitable radionuclide by means of a triamide thiolate (N_3S) or a diamide dithiolate (N_2S_2) chelate capable of administration to an animal to produce reliable diagnostic imaging of areas of potential restenosis.
10. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an imaging-effective amount of an antisense MCP-1 peptide labeled with a suitable radionuclide by means of a triamide thiolate (N_3S) or diamide dithiolate (N_2S_2) chelate to allow for diagnostic imaging of areas of potential restenosis.
11. An antisense MCP-1 peptide labeled with a suitable radionuclide by means of a triamide thiolate (N_3S) or a diamide dithiolate (N_2S_2) chelate.
12. The antisense MCP-1 peptide of claims 9, 10, or 11 wherein said antisense MCP-1 peptide labeled with a suitable radionuclide by means of a triamide thiolate (N_3S) or a diamide dithiolate (N_2S_2) chelate is capable of administration to a warm-blooded animal to produce reliable diagnostic imaging of areas of potential restenosis within two and one half hours post-injection.

13. A therapeutic composition suitable for administration to a warm-blooded animal comprising an antisense MCP-1 peptide labelled with a triamide thiolate (N_3S) or a diamide dithiolate (N_2S_2) chelate bound to a suitable radioactive isotope capable of administration to an animal to produce therapeutic effects on areas of potential restenosis.

14. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal a therapeutically-effective amount of an antisense MCP-1 peptide labeled with a triamide thiolate (N_3S) or a diamide dithiolate (N_2S_2) chelate bound to a suitable radioactive isotope to produce therapeutic effects on areas of potential restenosis.

15. An antisense MCP-1 peptide labeled with a triamide thiolate (N_3S) or a diamide dithiolate (N_2S_2) chelate bound to a radioactive isotope.

16. A composition suitable for administration to a warm-blooded animal comprising an antisense peptide with MCP-1 interactive capability capable of administration to an animal to produce therapeutic effects on areas of potential restenosis.


17. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal therapeutically-effective amount of an antisense peptide with MCP-1 interactive capability to produce therapeutic effects on areas of potential restenosis.

18. An antisense peptide with MCP-1 interactive capability to therapeutically inhibit vascular restenosis upon administration to a warm-blooded animal.

25


19. The antisense peptide with MCP-1 interactive capability of claims 16, 17, or 18 wherein said peptide labeled with a radionuclide by means of a triamide thiolate (N_3S) or a diamide dithiolate (N_2S_2) chelate is capable of administration to a warm-blooded animal to produce therapeutic effects on areas of potential restenosis.

20. A composition comprising antisense MCP-1 or an antisense peptide which retains MCP-1 interactive capability conjugated with a N_3S ligand having the general structure



wherein m is a whole number less than eleven; p is either 0 or 1; PG_1 is a sulfur protecting group selected from the group consisting of C_{1-20} S-acyl, C_{1-20} alkyl, C_{1-10} alkoxyalkyl, carbamoyl and C_{1-10} alkoxycarbonyl and X is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imidate, malaeimide, chlorocarbonyl, chlorosulfonyl, succinimidylloxycarbonyl, haloacetyl and C_{1-10} N-alkoxycarbamoyl.


21. A composition comprising antisense MCP-1 or an antisense molecule having MCP-1 interactive capability conjugated with a N_2S_2 ligand having the general structure



wherein n is a whole number less than eleven; PG_2 and PG_3


may be the same or different sulfur protecting groups selected from the group consisting of C_{1-20} S-acyl, C_{1-20} alkyl, C_{1-10} alkoxyalkyl, carbamoyl and C_{1-10} alkoxycarbonyl and Y is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imide, malaeimide, chlorocarbonyl, chlorosulfonyl, succinimidylloxycarbonyl, haloacetyl and C_{1-10} N-alkoxycarbamoyl.

22. A composition comprising antisense MCP-1 or an antisense molecule having MCP-1 interactive capability conjugated with a phenolic ligand having the general structure



wherein n is a whole number less than eleven; Y is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imide, malaeimide, chlorocarbonyl, chlorosulfonyl, succinimidylloxycarbonyl, haloacetyl and C_{1-10} N-alkoxycarbamoyl; and R is hydrogen or a C_{1-10} alkyl.

23. A composition comprising antisense MCP-1 or an antisense molecule having MCP-1 interactive capability conjugated with a metal complex having the general structure




wherein m is a whole number less than eleven; p is either 0 or 1; X' is a coupling moiety selected from the group

27

consisting of carboxyl, amino, isocyanate, isothiocyanate, imidate, malaeimide, chlorocarbonyl, chlorosulfonyl, succinimidyloxycarbonyl, haloacetyl and C_{1-10} N-alkoxycarbamoyl; and M is technetium, rhenium, indium, yttrium, gallium, samarium, holmium, copper or cobalt.


24. A composition comprising antisense MCP-1 or an antisense molecule having MCP-1 interactive capability conjugated with a metal complex having the general structure



10

wherein Y' is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imidate, malaeimide, chlorocarbonyl, chlorosulfonyl, succinimidyloxycarbonyl, haloacetyl and C_{1-10} N-alkoxycarbamoyl; n is a whole number less than eleven; and M is technetium, rhenium, indium, yttrium, gallium, samarium, holmium, copper or cobalt.


25. A composition comprising antisense MCP-1 or an antisense molecule having MCP-1 interactive capability conjugated with a metal complex having the general structure



wherein q is a whole number less than eleven; wherein Z' is a coupling moiety selected from the group consisting of carboxyl, amino, isocyanate, isothiocyanate, imidate,

malaeimide, chlorocarbonyl, chlorosulfonyl, succinimidylloxycarbonyl, haloacetyl and C₁₋₁₀ N-alkoxycarbamoyl; R is selected from the group consisting of hydrogen, and C₁₋₁₀ alkyl; and M is technetium, rhenium, indium, yttrium, gallium, samarium, holmium, copper or cobalt.

26. A composition comprising antisense MCP-1 or an antisense molecule having MCP-1 interactive capability conjugated with a metal complex having the general structure



wherein M is technetium, rhenium, indium, yttrium, gallium, samarium, holmium, copper or cobalt.

27. The composition of claim 23 labelled in a ^{99m}Tc-pertechnetate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

28. The composition of claim 24 labelled in a ^{99m}Tc-pertechnetate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

29. The composition of claim 25 labelled in a ^{99m}Tc-pertechnetate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

30. The composition of claim 26 labelled in a ^{99m}Tc-pertechnetate solution containing a reducing agent, a

buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

31. The composition of claim 27 labelled in a ^{99m}Tc -pertechnetate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

32. The composition of claim 28 labelled in a ^{99m}Tc -pertechnetate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

33. The composition of claim 29 labelled in a ^{99m}Tc -pertechnetate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

34. The composition of claim 23 labelled with ^{111}In -indium derivatives such as indium chloride, citrate or tartarate.

35. The composition of claim 24 labelled with ^{111}In -indium derivatives such as indium chloride, citrate or tartarate.

36. The composition of claim 25 labelled with ^{111}In -indium derivatives such as indium chloride, citrate or tartarate.

37. The composition of claim 26 labelled with ^{111}In -indium derivatives such as indium chloride, citrate or tartarate.

38. The composition of claim 27 labelled with ^{111}In -

indium derivatives such as indium chloride, citrate or tartarate.

39. The composition of claim 28 labelled with ¹¹¹In-indium derivatives such as indium chloride, citrate or
5 tartarate.

40. The composition of claim 29 labelled with ¹¹¹In-indium derivatives such as indium chloride, or tartarate.

41. The composition of claim 23 labelled in a 186/188 Re-perrheneate solution containing a reducing agent, a
10 buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

42. The composition of claim 24 labelled in a 186/188 Re-perrheneate solution containing a reducing agent, a
15 buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

43. The composition of claim 25 labelled in a 186/188 Re-perrheneate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

20 44. The composition of claim 26 labelled in a 186/188 Re-perrheneate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

45. The composition of claim 27 labelled in a 186/188
25 Re-perrheneate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.

46. The composition of claim 28 labelled in a 186/188 Re-perrhenate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.
- 5 47. The composition of claim 29 labelled in a 186/188 Re-perrhenate solution containing a reducing agent, a buffering agent, and a transfer ligand such as sodium gluconate or tartarate.
48. The composition of claim 23 labelled with ^{90}Yt
10 derivatives such as yttrium chloride, citrate or tartarate.
49. The composition of claim 24 labelled with ^{90}Yt derivatives such as yttrium chloride, citrate or tartarate.
50. The composition of claim 25 labelled with ^{90}Yt derivatives such as yttrium chloride, citrate or tartarate.
- 15 51. The composition of claim 26 labelled with ^{90}Yt derivatives such as yttrium chloride, citrate or tartarate.
52. The composition of claim 27 labelled with ^{90}Yt derivatives such as yttrium chloride, citrate or tartarate.
53. The composition of claim 28 labelled with ^{90}Yt
20 derivatives such as yttrium chloride, citrate or tartarate.
54. The composition of claim 29 labelled with ^{90}Yt derivatives such as yttrium chloride, citrate or tartarate.
55. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an
25 effective amount of the composition of claim 30 for diagnostic imaging of areas of potential restenosis.

56. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 31 for diagnostic imaging of areas of potential restenosis.

5 57. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 32 for diagnostic imaging of areas of potential restenosis.

58. A method of performing a diagnostic procedure,
10 which comprises administering to a warm-blooded animal an effective amount of the composition of claim 33 for diagnostic imaging of areas of potential restenosis.

59. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an
15 effective amount of the composition of claim 34 for diagnostic imaging of areas of potential restenosis.

60. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 35 for
20 diagnostic imaging of areas of potential restenosis.

61. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 36 for diagnostic imaging of areas of potential restenosis.

25 62. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 37 to produce therapeutic effects on areas of potential restenosis.

63. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 38 to produce therapeutic effects on areas of potential restenosis.
- 5 64. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 39 to produce therapeutic effects on areas of potential restenosis.
- 10 65. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 40 to produce therapeutic effects on areas of potential restenosis.
- 15 66. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 41 to produce therapeutic effects on areas of potential restenosis.
- 20 67. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 42 to produce therapeutic effects on areas of potential restenosis.
68. A method of performing a therapeutic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 43 to produce therapeutic effects on areas of potential restenosis.
- 25 69. The composition of claim 26, wherein M is ^{99m}technetium.
70. The composition of claim 27, wherein M is ^{99m}technetium.

71. The composition of claim 28, wherein M is ^{99m}technetium.
72. The composition of claim 29, wherein M is ^{99m}technetium.
- 5 73. The composition of claim 26, wherein M is indium-111.
74. The composition of claim 27, wherein M is indium-111.
75. The composition of claim 28, wherein M is
10 indium-111.
76. The composition of claim 29, wherein M is indium-111.
77. The composition of claim 26, wherein M is rhenium-186 or rhenium-188.
- 15 78. The composition of claim 27, wherein M is rhenium-186 or rhenium-188.
79. The composition of claim 28, wherein M is rhenium-186 or rhenium-188.
80. The composition of claim 29, wherein M is
20 rhenium-186 or rhenium-188.
81. The composition of claim 26, wherein M is yttrium-90.
82. The composition of claim 27, wherein M is yttrium-90.

83. The composition of claim 28, wherein M is yttrium-90.

84. The composition of claim 29, wherein M is yttrium-90.

5 85. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 44 to image areas of potential restenosis.

86. A method of performing a diagnostic procedure,
10 which comprises administering to a warm-blooded animal an effective amount of the composition of claim 45 to image areas of potential restenosis.

87. A method of performing a diagnostic procedure,
15 which comprises administering to a warm-blooded animal an effective amount of the composition of claim 46 to image areas of potential restenosis.

88. A method of performing a diagnostic procedure,
20 which comprises administering to a warm-blooded animal an effective amount of the composition of claim 47 to image areas of potential restenosis.

89. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 48 to image areas of potential restenosis.

25 90. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 49 to image areas of potential restenosis.

91. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 50 to image areas of potential restenosis.

5 92. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 51 to image areas of potential restenosis.

10 93. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 52 to image areas of potential restenosis.

15 94. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 53 to image areas of potential restenosis.

20 95. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 54 to image areas of potential restenosis.

96. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 55 to image areas of potential restenosis.

25 97. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 56 to image areas of potential restenosis.

98. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of the composition of claim 57 to image areas of potential restenosis.

5 99. A composition suitable for administration to a warm-blooded animal comprising an antisense MCP-1 oligonucleotide or a derivative thereof to inhibit vascular restenosis.

10 100. A method of in vivo vascular therapy, which comprises administering to a warm-blooded animal a therapeutically effective amount of an antisense MCP-1 oligonucleotide or a derivative thereof to inhibit vascular restenosis.

15 101. An antisense MCP-1 oligonucleotide capable of inhibiting vascular restenosis upon in vivo administration.

20 102. The antisense MCP-1 oligonucleotide of claim 99, 100 or 102 wherein said antisense MCP-1 oligonucleotide is labeled with Phosphorus -32 or Phosphorus -33 is capable of administration to a warm-blooded animal to inhibit vascular restenosis.

103. A plasmid construct consisting of antisense MCP-1 oligonucleotide linked to a smooth muscle actin promoter capable of replication within smooth muscle cells to produce therapeutic effects on smooth muscle cells.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10074

A. CLASSIFICATION OF SUBJECT MATTER

IPC(S) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 24.1, 24.5; 514/2, 12, 44; 530/300, 324; 424/1.1; 435/320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS, BIOSIS, MEDLINE, LIFESCI, EMBASE, BIOTECHDS

search terms: monocyte chemotactic or mcp, antisense

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BIOCHEMISTRY, Volume 28, issued November 1989, Y. Shai et al., "Antisense Peptide Recognition of Sense Peptides: Sequence Simplification and Evaluation of Forces Underlying the Interaction", pages 8804-881, entire document.	1-98
A	TRENDS IN BIOTECHNOLOGY, Volume 8, issued July 1990, J.E. Blalock, "Complementarity of Peptides Specified By 'Sense' and 'Antisense' Strands of DNA", pages 140-144, entire document.	1-98

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

21 January 1994

Date of mailing of the international search report

10 FEB 1994

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Authorized officer

ROBERT WAX

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10074

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,037,630 (Fritzberg et al.) 06 August 1991, entire document.	4,9-15,19, 21,24,28,32,35,3 9,42,46,49,53,57 ,60, 64,67,71,75, 79,84,87,90, 94,98
A	US, A, 4,965,392 (Fritzberg et al.) 23 October 1990, entire document.	4-15,19,20, 23,26,27,30,31,3 4,37,38,41,44,45 ,48,51,52,55,56, 59,52,63,66,69,7 0,73,74,77,78,81 ,82,85,86,89,92, 93,96,97
A	BLOOD, Volume 78, No. 4, issued 15 August 1991, B.J. Rollins et al. "Recombinant Human MCP-1/JE Induces Chemotaxis, Calcium Flux, and the Respiratory Burst in Human Monocytes", pages 1112-1116, entire document.	1-103
A	MOLECULAR AND CELLULAR BIOLOGY, Volume 11, No. 6, issued June 1991, B.J. Rollins et al. "Suppression of Tumor Formation In Vivo by Expression of the JE Gene in Malignant Cells", pages 3125-3131, entire document.	1-103
A	CHEMICAL REVIEWS, Volume 90, No. 4, issued June 1990, E. Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle", pages 543-584, entire document.	99-103

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10074

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
(Telephone Practice)

- I. Claims 1-98, drawn to antisense peptides and methods of use, classified in Class 530, subclass 300
- II. Claims 99-103, drawn to antisense oligonucleotides and methods of use, classified in Class 536, subclass 23.1.

Groups I and II lack unity under PCT rules 13.1-13.2 because the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept. Note that PCT Rule 13 does not provide for multiple products or methods within a single application.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10074

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C12N 15/11, 15/85; C07H 21/04; C07K 15/00, C07K15/12; A61K 37/02, 31/73, 43/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

536/23.1, 24.1, 24.5; 514/2, 12, 44; 530/300, 324; 424/1.1; 435/320.1